F Strasser1, D Blum2, R von Moos3, R Cathomas3, K Ribi4, S Aebi5, D Betticher6, S Hayoz7, D Klingbiel7, P Brauchli7, M Haefner8, S Mauri9, S Kaasa10, D Koeberle11. 1. Oncological Palliative Medicine, Clinic Oncology/Hematology, Department of Internal Medicine and Palliative Center, Cantonal Hospital St Gallen, St Gallen, Switzerland florian.strasser@kssg.ch. 2. Oncological Palliative Medicine, Clinic Oncology/Hematology, Department of Internal Medicine and Palliative Center, Cantonal Hospital St Gallen, St Gallen, Switzerland European Palliative Research Centre, NTNU, and St Olavs University Hospital Trondheim, Trondheim, Norway. 3. Department of Oncology, Cantonal Hospital Chur, Chur. 4. IBCSG, Bern. 5. Department of Oncology, University Hospital Bern, Bern. 6. Department of Oncology, Cantonal Hospital Fribourg, Fribourg. 7. SAKK Coordinating Center, Bern. 8. Department of Oncology, Bülach. 9. Department of Oncology, Cantonal Hospital Lugano, Lugano. 10. European Palliative Research Centre, NTNU, and St Olavs University Hospital Trondheim, Trondheim, Norway. 11. Clinic Oncology/Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
Abstract
BACKGROUND:Patients with advanced, incurable cancer receiving anticancer treatment often experience multidimensional symptoms. We hypothesize that real-time monitoring of both symptoms and clinical syndromes will improve symptom management by oncologists and patient outcomes. PATIENTS AND METHODS: In this prospective multicenter cluster-randomized phase-III trial, patients with incurable, symptomatic, solid tumors, who received new outpatient chemotherapy with palliative intention, were eligible. Immediately before the weekly oncologists' visit, patients completed the palm-based E-MOSAIC assessment (Edmonton-Symptom-Assessment-Scale, ≤3 additional symptoms, estimated nutritional intake, body weight change, Karnofsky Performance Status, medications for pain, fatigue, nutrition). A cumulative, longitudinal monitoring sheet (LoMoS) was printed immediately. Eligible experienced oncologists were defined as one cluster each and randomized to receive the immediate print-out LoMoS (intervention) or not (control). Primary analysis limited to patients having uninterrupted (>4/6 visits with same oncologist) patient-oncologist sequences was a mixed model for the difference in patients global quality of life (G-QoL; items 29/30 of EORTC-QlQ-c30) between baseline (BL) and week 6. Intention-to-treat (ITT) analysis included all eligible patients. RESULTS: In 8 centers, 82 oncologists treated 264 patients (median 66 years; overall survival intervention 6.3, control 5.4 months) with various tumors. The between-arm difference in G-QoL of 102 uninterrupted patients (intervention: 55; control: 47) was 6.8 (P = 0.11) in favor of the intervention; in a sensitivity analysis (oncologists treating ≥2 patients; 50, 39), it was 9.0 (P = 0.07). ITT analysis revealed improvement in symptoms (difference last study visit-BL: intervention -5.4 versus control 2.1, P = 0.003) and favored the intervention for communication and coping. More patients with high symptom load receivedimmediate symptom management (chart review, nurse-patient interview) by oncologists getting the LoMoS. CONCLUSION: Monitoring of patient symptoms, clinical syndromes and their management clearly reduced patients' symptoms, but not QoL. Our results encourage the implementation of real-time monitoring in the routine workflow of oncologist with a computer solution.
RCT Entities:
BACKGROUND:Patients with advanced, incurable cancer receiving anticancer treatment often experience multidimensional symptoms. We hypothesize that real-time monitoring of both symptoms and clinical syndromes will improve symptom management by oncologists and patient outcomes. PATIENTS AND METHODS: In this prospective multicenter cluster-randomized phase-III trial, patients with incurable, symptomatic, solid tumors, who received new outpatient chemotherapy with palliative intention, were eligible. Immediately before the weekly oncologists' visit, patients completed the palm-based E-MOSAIC assessment (Edmonton-Symptom-Assessment-Scale, ≤3 additional symptoms, estimated nutritional intake, body weight change, Karnofsky Performance Status, medications for pain, fatigue, nutrition). A cumulative, longitudinal monitoring sheet (LoMoS) was printed immediately. Eligible experienced oncologists were defined as one cluster each and randomized to receive the immediate print-out LoMoS (intervention) or not (control). Primary analysis limited to patients having uninterrupted (>4/6 visits with same oncologist) patient-oncologist sequences was a mixed model for the difference in patients global quality of life (G-QoL; items 29/30 of EORTC-QlQ-c30) between baseline (BL) and week 6. Intention-to-treat (ITT) analysis included all eligible patients. RESULTS: In 8 centers, 82 oncologists treated 264 patients (median 66 years; overall survival intervention 6.3, control 5.4 months) with various tumors. The between-arm difference in G-QoL of 102 uninterrupted patients (intervention: 55; control: 47) was 6.8 (P = 0.11) in favor of the intervention; in a sensitivity analysis (oncologists treating ≥2 patients; 50, 39), it was 9.0 (P = 0.07). ITT analysis revealed improvement in symptoms (difference last study visit-BL: intervention -5.4 versus control 2.1, P = 0.003) and favored the intervention for communication and coping. More patients with high symptom load received immediate symptom management (chart review, nurse-patient interview) by oncologists getting the LoMoS. CONCLUSION: Monitoring of patient symptoms, clinical syndromes and their management clearly reduced patients' symptoms, but not QoL. Our results encourage the implementation of real-time monitoring in the routine workflow of oncologist with a computer solution.
Authors: Stephanie L Pugh; Joseph P Rodgers; Katherine A Yeager; Ronald C Chen; Benjamin Movsas; Roseann Bonanni; James Dignam; Deborah W Bruner Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-24 Impact factor: 7.038
Authors: R D Nipp; A El-Jawahri; M Ruddy; C Fuh; B Temel; S M D'Arpino; B J Cashavelly; V A Jackson; D P Ryan; E P Hochberg; J A Greer; J S Temel Journal: Ann Oncol Date: 2019-02-01 Impact factor: 32.976
Authors: Grant R Williams; Kathryn E Weaver; Glenn J Lesser; Emily Dressler; Karen M Winkfield; Heather B Neuman; Anne E Kazak; Ruth Carlos; Lucy J Gansauer; Charles S Kamen; Joseph M Unger; Supriya G Mohile; Heidi D Klepin Journal: Oncologist Date: 2020-08-31
Authors: Ashley M Henneghan; Chris Gibbons; Rebecca A Harrison; Melissa L Edwards; Vikram Rao; Douglas W Blayney; Oxana Palesh; Shelli R Kesler Journal: Brain Topogr Date: 2019-11-19 Impact factor: 3.020
Authors: Markus K Schuler; Freya Trautmann; Mirko Radloff; Roman Schmädig; Leopold Hentschel; Maria Eberlein-Gonska; Thomas Petzold; Heike Vetter; Sebastian Oberlack; Gerhard Ehninger; Jochen Schmitt Journal: Support Care Cancer Date: 2016-03-16 Impact factor: 3.603
Authors: Hilde Krogstad; Stine Marie Sundt-Hansen; Marianne Jensen Hjermstad; Liv Ågot Hågensen; Stein Kaasa; Jon Håvard Loge; Sunil X Raj; Aslak Steinsbekk; Kari Sand Journal: Support Care Cancer Date: 2018-09-01 Impact factor: 3.603